Screening Criteria Miss 65% of Lung Cancer
A new JAMA Network Open study of 89,860 patients proves the hard truth: our screening guidelines were built around smoking history, not around who actually gets this disease.
Lung cancer kills more Americans than any other cancer. 229,410 new cases are projected in 2026. 124,990 people will die. And we have a screening test - low-dose CT - that catches it early, when Stage I survival is 77% and Stage IV survival is 9%.
So why are we still screening the wrong people?
A study published July 21, 2026 in JAMA Network Open answers that question with uncomfortable precision. Researchers at Seoul National University Bundang Hospital analyzed 89,860 patients diagnosed with lung cancer in South Korea between 2013 and 2018. Then they asked one question: how many of these actual lung cancer patients would have been eligible for screening under established guidelines from the USPSTF, ACS, and NCCN?
The answer: 35.4%.
Sixty-five percent of people who actually got lung cancer would not have been invited to the screening that might have saved them.
📊 This is not a data artifact. This is a structural failure in how we define risk.
1. What the Study Actually Found
The JAMA Network Open study is the largest retrospective analysis of lung cancer screening eligibility versus actual diagnosis in any Asian population. It is also, by the numbers, the most direct indictment of current screening criteria published to date.
Key findings from 89,860 confirmed lung cancer patients:
64.6% would NOT have qualified for LDCT screening under international guidelines
Only 35.4% (31,804 patients) met eligibility criteria
44.1% of diagnosed patients had no smoking history at all
4.7% were diagnosed before age 50
The sex disparity is where the data becomes most damning. Among patients aged 50 to 80 - the core screening window - eligibility looked like this:
Men aged 50 to 80: 56.8% would have been eligible for screening. Women aged 50 to 80: 2.3% would have been eligible for screening.
Read that again. Of all the women who got lung cancer in this study, fewer than 1 in 40 would have qualified for a screening scan under current criteria.
The researchers also surfaced something unexpected in the survival data. Never-smokers had 14% lower all-cause mortality and lung cancer-specific mortality than eligible smokers. Ineligible smokers had 5% lower all-cause mortality than eligible smokers.
The people we designed our system to exclude were dying at lower rates than the ones we designed it to find. That does not mean they were fine - it means we caught them later and lost more of them to late-stage disease.
2. This Is Not a Korean Problem
The instinct when reading studies from South Korea is to discount their relevance to U.S. practice. Smoking patterns differ. Genetics differ. Air quality differs.
But the pattern holds in American data too.
Northwestern Medicine researchers published a parallel finding in late 2025: only 35% of consecutive lung cancer patients at Northwestern would have qualified for USPSTF screening. Two-thirds were excluded - disproportionately women and never-smokers. Their recommendation was unambiguous: move to universal age-based screening from 40 to 85, which their modeling showed would detect 94% of lung cancers and prevent more than 26,000 extra deaths annually.
Twenty-six thousand extra deaths annually. Preventable with a different eligibility threshold.
The scale of the gap in the United States is staggering. The American Cancer Society projects 118,500 American women will be diagnosed with lung cancer in 2026. Of those, roughly 24% are non-smokers. That is approximately 28,400 women who have never smoked - or smoked very little - and who are essentially invisible to our current screening framework.
In Asia, never-smokers account for 30% or more of all lung cancer cases. In the United States, 10 to 20% of all lung cancers - between 20,000 and 40,000 cases per year - occur in people who have never smoked. Women account for two-thirds of never-smoker lung cancer cases.
These are not edge cases. These are tens of thousands of people per year who will be diagnosed at Stage III or Stage IV because no one sent them for a scan.
📊 National LDCT screening rate among USPSTF-eligible Americans: approximately 6%. For never-smokers: 0%.
3. How the Guidelines Became the Problem
Current USPSTF criteria (updated in 2021) require: - Age 50 to 80 - 20 pack-year smoking history - Currently smoking or quit within the past 15 years
The 2021 update was a genuine improvement. It expanded the age floor from 55 to 50 and reduced the pack-year threshold from 30 to 20. That change roughly doubled the number of eligible women and significantly expanded eligibility for Black and Hispanic Americans.
But the underlying architecture remained: you have to be a current or recent heavy smoker to qualify.
That architecture was designed with a specific goal: target the highest-risk individuals while avoiding overdiagnosis from false positives in lower-risk groups. The logic was sound when the evidence base was limited.
The evidence base is no longer limited.
We now know that: - Never-smokers represent 10-20% of all U.S. lung cancers - Women get lung cancer at higher rates than the smoking-only risk model predicts - Environmental exposures (radon, air pollution, cooking fumes) are significant independent risk factors - Asian women who have never smoked are twice as likely to develop lung cancer as female non-smokers of other ethnicities - Genetics - particularly EGFR mutations - drive a distinct lung cancer phenotype seen disproportionately in women and never-smokers
The guidelines have not caught up to the science. And people are dying in the gap.
4. The FQHC and Community Health Dimension
This is where the story gets harder.
Even for people who DO qualify under current criteria, the screening system fails them regularly. The national LDCT screening rate among eligible Americans sits around 6%. In 2022, only 0.69% of USPSTF-eligible participants actually completed lung cancer screening.
The access failure is largest at the bottom of the income distribution - exactly where Federally Qualified Health Centers operate.
FQHC patients face layered barriers to screening access. Many lack insurance that covers LDCT. They lack transportation to imaging centers. They lack the care coordinators and patient navigators who translate a physician's recommendation into an actual completed scan. They work jobs that do not allow for appointment flexibility. And they are disproportionately women and people of color - the exact groups already excluded by the criteria.
A 2025 quality improvement study at a resident-run FQHC found that with targeted patient outreach and electronic health record care gap optimization, monthly LDCT completion rates shifted from near-zero to 12.3 scans per month. That is a meaningful gain - and it required sustained investment in outreach infrastructure that most FQHCs do not have.
If the criteria were expanded to include never-smokers and younger patients, the FQHC access gap would widen further - unless we simultaneously invest in the navigation infrastructure to get those newly eligible patients into scanners.
This is the two-part problem: criteria that exclude the wrong people, and a delivery system that fails even the people the criteria include.
5. The Survival Math That Justifies Action
If you work in healthcare, you know the stage-survival numbers for lung cancer. They are the most important numbers in oncology and among the least acted upon.
Stage I lung cancer: 64-82% five-year survival. Stage IV lung cancer: 7-9% five-year survival.
The gap between those two numbers is the economic and moral case for screening reform. It is not a marginal improvement. It is a 10x difference in who lives.
The NLST trial - the landmark study that established LDCT screening - demonstrated a 20% reduction in lung cancer mortality in high-risk smokers. That evidence base has since been extended and confirmed.
But the NLST enrolled smokers. If 65% of lung cancer patients do not qualify for screening under current criteria, the NLST evidence only applies to one third of the people who will die.
The question for health system leaders and policymakers is not whether to screen. It is whether to screen only for smokers - when the disease has clearly outgrown that definition.
Deep Dive
The Case for Age-Based Screening - What the Numbers Show
Northwestern Medicine's 2025 advocacy case laid out the arithmetic for universal age-based screening from 40 to 85:
Current USPSTF approach: Detects roughly 35-37% of patients who will develop lung cancer. Misses 63-65% of actual cases. Screening rate among eligible: ~6%. Total lives saved from current program: meaningful but limited.
Age-based universal approach (40-85): Would detect approximately 94% of lung cancers. Would prevent an estimated 26,000+ additional deaths annually. Requires no pack-year calculation. Eliminates the sex and smoking status disparity entirely.
The counterargument is false positive rate and overdiagnosis. LDCT produces a meaningful number of incidental findings requiring follow-up. Expanding screening to never-smokers and younger patients would increase the total number of scans and the absolute number of false positives.
That is a real concern - and it is manageable.
The answer to false positives is better AI-assisted nodule characterization, not fewer scans. CPT 0721T - the CMS reimbursement code for AI-assisted lung CT analysis - was specifically designed to improve the accuracy of nodule risk stratification. Better scoring means fewer unnecessary biopsies, fewer unnecessary follow-ups, and a better signal-to-noise ratio from a larger screening pool.
The Oatmeal Health model operationalizes exactly this: identify high-risk patients in FQHC populations, get them scanned under CPT 0721T, and score every nodule for malignancy risk. The JAMA study data suggests that high-risk patient identification can no longer rely solely on smoking history.
What a Criteria Expansion Would Mean for the Industry
If USPSTF expanded criteria to include never-smokers with risk factors, or moved to age-based universal screening from 40-85, the implications would cascade across the healthcare system.
For radiologists: Scan volume would increase substantially. The current ~6% screening rate among eligible Americans is already generating LDCT backlogs. Universal eligibility would require AI-assisted reading workflows - not as an enhancement, but as an operational necessity.
For health systems: Earlier-stage diagnoses would shift the treatment mix toward surgery and ablative therapy and away from late-stage chemotherapy and immunotherapy. Stage I treatment costs significantly less than Stage IV. The economic argument for screening investment is already positive even under current criteria - it becomes stronger as eligibility expands.
For FQHCs: The population served by community health centers is exactly the population missed by current criteria. Low-income women. Non-smokers with environmental exposures. Immigrants from Asia where never-smoker lung cancer rates are highest. Criteria expansion would convert millions of currently ineligible patients into patients with a covered screening benefit - if the navigation infrastructure is in place.
For payers: The short-term cost of more scans is real. The long-term cost of Stage IV lung cancer - immunotherapy, targeted agents, hospitalizations, palliative care - is vastly higher. The actuarial case for prevention has been made for colorectal cancer and breast cancer. Lung cancer is overdue.
What This Means For You
For FQHC executives and community health center leaders: Audit your lung cancer screening program against both current USPSTF criteria AND the population your center actually serves. If your patient mix includes significant numbers of women over 50, Asian patients, or patients with environmental exposure histories (radon, cooking fuel, occupational hazards), you likely have a substantial unscreened population. Patient navigation investment pays off - the FQHC quality improvement data is clear on this.
For health system administrators and CMOs: Begin planning for criteria expansion now. The JAMA Network Open study and Northwestern findings are building the evidentiary case for broader guidelines. That change is coming - the only question is timeline. Health systems that build AI-assisted screening capacity and care navigation now will be positioned to absorb increased volume without quality degradation.
For radiologists and pulmonologists: The never-smoker lung cancer phenotype is clinically distinct. EGFR mutations are more common. Adenocarcinoma is the dominant histology. Younger patients. Less comorbidity. These are not the same patients as the heavy smoker NLST cohort - and their CT findings may look different. Continuing education on never-smoker lung cancer patterns is no longer optional.
For healthcare investors and founders: The screening criteria reform story is investable. AI-assisted nodule characterization, patient risk stratification outside smoking history, and care navigation technology for newly eligible populations are all compelling categories. The JAMA data puts numbers on a gap that has been qualitatively understood for years.
For policy advocates: The comment period for the 2027 CMS Physician Fee Schedule closes September 14, 2026. This is an opportunity to submit comments supporting lung cancer screening reimbursement reform that reflects current evidence. CPT 0721T billing expansion, coverage for never-smokers with documented risk factors, and care navigation reimbursement are all actionable policy levers.
Closing
The JAMA Network Open study does not tell us anything the field did not already suspect. Screening criteria built around heavy smokers were always going to miss never-smokers. A sex eligibility gap of 56.8% versus 2.3% was always going to miss women.
What the study does is put a number on it - 65% - and put it on the record in the highest-impact medical journal in the world.
That number now has to be defended. Every pulmonology chief, every health system CMO, every FQHC medical director who looks at that number and does not change something is making a choice.
Lung cancer kills 125,000 Americans per year. The survival math is brutal: catch it at Stage I, three in four patients live. Catch it at Stage IV, nine in ten die.
The criteria we are using to decide who gets screened are currently keeping two-thirds of patients in the wrong column.
That is not a guideline problem. It is a political will problem.
What is your system doing about the 65%?
About the Author
Jonathan Govette is the Co-Founder and CEO of Oatmeal Health, an AI lung cancer diagnostic company catching cancers earlier in the communities that need it most. Oatmeal uses AI to identify unscreened high-risk patients, navigate them to care, and score every lung CT for malignancy risk - billed under CPT 0721T. Stage I survival is 77%. Stage IV is 9%. We work in FQHCs because that gap is largest there.
Jonathan writes daily about radiology, pulmonology, AI diagnostics, health policy, hospital operations, and healthcare startups.
Subscribe to stay ahead of healthcare's most important shifts. Weekly deep-dives on AI, radiology, health policy, FQHCs, and the business of healthcare - written for operators, clinicians, and investors who want the signal, not the noise. Subscribe at oatmealhealthjonathangovette.substack.com
Key References
JAMA Network Open, July 21 2026 - "Screening Eligibility and Survival Among Patients With Lung Cancer in Korea" - 89,860-patient retrospective cohort study, Seoul National University Bundang Hospital
The Imaging Wire, July 22 2026 - "Lung Cancer Mystery in Non-Smokers" - https://theimagingwire.com/2026/07/22/lung-cancer-screening-criteria-would-have-missed-two-thirds-of-lung-cancers/
Northwestern Medicine, November 2025 - "New Study Shows Lung Cancer Surveillance in the United States Misses Most Patients" - Universal age-based screening (40-85) would prevent 26,000+ extra deaths/year
American Cancer Society Cancer Facts and Figures 2026 - 229,410 projected lung cancer cases, 124,990 deaths, 118,500 women affected
AuntMinnie, July 2026 - "LDCT screening criteria miss majority of Korean lung cancer patients" - confirms 64.6% ineligibility finding